Wednesday, July 8, 2026

Drug profile · INN

amdinocillin

amdinocillin (COACTIN) is a bacterial penicillin-binding protein 2 inhibitor. Route of administration: injection. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 1
News articles 0
Drug details — amdinocillin
US status
approved
Class
Route
INJECTION
Patents
0
Programs
1
Data quality
0.84

Quick answer

amdinocillin (COACTIN) is a bacterial penicillin-binding protein 2 inhibitor. Route of administration: injection. Current US regulatory status: approved.

Key facts

INN amdinocillin
Brand COACTIN
Mechanism Bacterial penicillin-binding protein 2 inhibitor
Target Peptidoglycan D,D-transpeptidase MrdA
Route INJECTION
Formulation INJECTABLE

Mechanism of action

Bacterial penicillin-binding protein 2 inhibitor

Primary target: Peptidoglycan D,D-transpeptidase MrdA

Approval history

Authority Status Date
FDA approved

Pipeline programs

  1. OCT Unknown · Cardiff Oncology · AMD

Related & competitor drugs

  1. pivmecillinam hydrochloride Bacterial penicillin-binding protein 2 inhibitor

Frequently asked questions

What is amdinocillin?

amdinocillin (COACTIN) is a bacterial penicillin-binding protein 2 inhibitor. Route of administration: injection. Current US regulatory status: approved.

What is the brand name for amdinocillin?

COACTIN is a marketed brand name for amdinocillin. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of amdinocillin?

amdinocillin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.